The drug delivered higher reductions in LDL cholesterol than can currently be achieved with any other drug or intervention.
Showing 25 of 1675
Mediclinic noted reported comments by the crown prince of Abu Dhabi ordering the waiving of a 20% co-payment for holders of a Thiqa medical insurance card
Copycat competition for big sellers such as cholesterol-buster Crestor ate into first quarter revenues, which fell by 12% to US$5.54bn in the first-quarter.
The FTSE 100-listed firm said its adjusted earnings per share rose by 31% to 25.0p in the quarter to March 31, beating forecasts for 24.5p
Higher volumes from key customers and strong demand for pericardium tissue were behind the surge.
Doug Doerfler, MaxCyte’s chief executive, said: "We are excited by these results, and look forward to evaluating long-term data."
The company said it made significant progress last year, with early revenues and a promising development pipeline.
The deal validates the licensing model, says chief executive, Dr Alastair Smith
The EASE study will assess the progress of 164 patients across 30 sites in 15 countries with Sydney, Australia, the first to begin work
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
Iclaprim is one of the next-generation of antibiotics and it will be used, initially at least, to treat acute bacterial skin and skin structure infections
The REVIVE-1 global study assessed the drug’s ability to treat patients with acute bacterial skin and skin structure infections
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
CellPlan, Widecell’s stem cell insurance product is ahead of management expectations
Second-half sales of the PIFA PF/4 device were strong as the company targeted hospitals in the US and generated a significant early revenues from China.
“We and consensus have been guilty of failing to reflect the impact of future revenue externalisation and asset disposals on revenue and earnings per share growth,” said analyst Jeffrey Holford.
Jazz will grant Hikma and its wholly-owned subsidiary West-Ward Pharmaceuticals Corp the right to sell an authorised generic version of Xyrem in the US from the beginning of January 2023
Dr Raymond Barlow arrives from Amgen, where he held a senior role
The shares, listed at 9p each, were changing hands for 13.75p in early afternoon, valuing the business at a tad over £16mln.
The share placing follows a period of expansion that has seen it make two major acquisition
The shares, sold to investors at 5p each, were changing hands for 5.5p early on
McCarthy & Stone said sales momentum has improved in the past five weeks after first half trading was affected by a lower forward order book
The share placing follows a period of expansion that has seen it make two major acquisition since its 2014 listing that have significantly increased the company’s scale.
Data from the European head and neck trial with lead product NBTXR3 will be presented at the ASCO meeting in June
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets